In 1996, they demonstrated that the in vivo administration of antibodies against CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) resulted in tumor rejection [1], and was termed the so-called “checkpoint blockade immunotherapies”. Here, CTLA4 is linked to neoplasm.